ASCO 2018 Highlight (Conference Call)

from the beginning

Opening

Transforming into Oncology

Forward-looking Statements

Our History and the Path to Merger

With Continued Focus on Discovery…

Becoming a Competitive Force by Establishing Strength & Expertise in Diverse Modalities

Making Progress & Realizing the 2025 Vision in Oncology

Exceptional Progress & Momentum in our ADC Franchise

DS-8201 | Most Recent Data

DS-8201 | Strategic Collaboration with AstraZeneca

DS-8201 | Strategic Collaboration … Our Intent

DS ADC Technology: Platform Technology

DS RD Capability

@

ASCO2019 Highlights

Today’s Agenda

• ・DS-8201

Daiichi Sankyo AstraZeneca DS-8201 Collaboration

DS-8201 | HER2 mBreast Cancer Post T-DM1 Submissions Plan

DS-8201 | HER2 Gastric Cancer Submission Plan

DS-8201 | Remarkable Speed in Development & Manufacturing

DS-8201 | Redefining HER2 in Breast Cancer & Beyond

DS-8201 | HER2+ Breast & Gastric P1 Cohorts

DS-8201 | April 29, 2019 Lancet Oncology Editorial

DS-8201 | P1 Study Lancet Oncology Breast Cancer

DS-8201 | P1 Study Lancet Oncology Gastric Cancer

DS-8201 | Safety: ILD

• ・U3-1402 & DS-1062

Daiichi Sankyo ADC Franchise (as of June 2019)

U3-1402 Phase 1 Dose Escalation and Expansion Study

Baseline Characteristics of Patients Treated with U3-1402

TEAEs and DLTs in Patients Treated with U3-1402

Safety Summary of Patients Treated with U3-1402

U3-1402 Antitumor Activity Across Diverse EGFR-TKI Resistance Mechanisms

U3-1402 Antitumor Activity Across Diverse EGFR-TKI Resistance Mechanisms

U3-1402 Antitumor Activity Over Time

U3-1402 Treatment Duration

U3-1402 Patient Case

U3-1402 NSCLC | What it Means for Us

2 U3-1402 & DS-1062

DS-1062 | TROP2 DXd ADC with Selective DAR4

DS-1062 | In vitro Cell Growth Inhibitory Activity

DS-1062 | Anti-Tumor Activity in Xenograft Mice Models

DS-1062 | Contrast with Sacituzumab Govitecan

DS-1062 | TROP2 Targeted ADC Dose Escalation in Relapsed NSCLC

: MTD Not Reached Safety Summary, Number of Patients with TEAEs (in 10% of patients), Regardless of Causality

Objective responses emerging at >2mg/kg dose Anti-tumor Activity

CT Scan Findings in Dose Escalation

CT Scan Findings in Dose Escalation

CT Scan Findings in Dose Escalation

CT Scan Findings in Dose Escalation

Dose / Effect Spider Plot (preliminary data April 12, 2019)

DS-1062 NSCLC | What it Means for Us

• ・DS-7300 & DS-6157

DS-7300 | B7-H3 Targeted ADC to Enter Clinic in FY2019

DS-6157 | GPR20 ADC

• ・Regulatory Reviews

Pexidartinib in TGCT Clinical Benefit

ASCO 2019: Updated Efficacy in TGCT

ASCO 2019: Updated Safety in TGCT (ENLIVEN and Phase 1)

Pexidartinib

Quizartinib

• ・Rest of the Portfolio

AML / HEM Franchise Continues to Progress

MajorR&D Pipeline in Oncology (As of June 2019)

Upcoming Milestones

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4